Gene
SULF2
SULF2 is a gene biomarker in the evidence tier "FDA companion diagnostic". This page lists evidence by type: FDA companion diagnostic assertions (1), Assay-provider ledger (5), Trial mentions (13), and 5 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
4 sections measured, none recorded
FDA companion diagnostic
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention SULF2. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 0 of 8,597 | 0.00% | not measured | |
| 2023 | 1 of 8,275 | 0.01% | 2 of 11,460 | 0.02% |
| 2022 | 0 of 8,285 | 0.00% | 1 of 13,598 | 0.01% |
| 2021 | 0 of 8,692 | 0.00% | 1 of 15,045 | 0.01% |
| 2020 | 0 of 7,640 | 0.00% | 1 of 14,459 | 0.01% |
| 2019 | 1 of 7,300 | 0.01% | 0 of 12,159 | 0.00% |
| 2018 | 0 of 6,927 | 0.00% | 1 of 11,854 | 0.01% |
| 2017 | 1 of 6,558 | 0.02% | 0 of 11,595 | 0.00% |
Showing 10 of 37 years.
FDA companion diagnostic assertions (1)
Shown in this order: most recent decision first.
| Diagnostic | Source biomarker wording | Manufacturer | Indication | Decision date |
|---|---|---|---|---|
| Idylla CDx MSI Test | SULF2 | Biocartis US, Inc. | Colorectal Cancer (CRC) | 2025-08-15 |
Assay-provider ledger (5)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Biocartis | Diagnostic provider | Clinical validation | 3 | September 01, 2025 |
| Agilent Technologies | Reagent supplier | Clinical validation | 1 | July 24, 2021 |
| DAKO (Carpinteria, CA, USA) - IHC antibodies and Autostainer Link 48 platform | Context dependent | Clinical validation | 1 | July 24, 2021 |
| Diatech Pharmacogenetics | Diagnostic provider | Clinical validation | 1 | July 24, 2021 |
| Qiagen (Hilden, Germany) - Mini Amp DNA extraction kit | Reagent supplier | Clinical validation | 1 | July 24, 2021 |
Trial mentions (13)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT01626092 | Trial eligibility (AACT) |
| NCT01510028 | Trial eligibility (AACT) |
| NCT01325025 | Trial eligibility (AACT) |
| NCT03370653 | Trial eligibility (AACT) |
| NCT01050439 | Trial eligibility (AACT) |
Showing 5 of 13 trial mentions.
Target-disease associations (240)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| (R)-3-hydroxybutyrylcarnitine measurement | measurement | GWAS credible sets |
| Abnormality of the gastrointestinal tract | phenotype | GWAS credible sets |
| Alkalosis | phenotype | GWAS credible sets |
| Alzheimer disease | nervous system disease | Literature (Europe PMC) |
| Barrett's esophagus | gastrointestinal disease | Mouse knockout (IMPC) |
Showing 5 of 240 associations.
Vendor sourcing (35)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.1225C>T (p.R409W) alteration is located in exon 9 (coding exon 8) of the SULF2 gene. This alteration results from a C to T substitution at nucleotide p... | View ClinVar record SCV003537860.2 |
| Assistance Publique – Hôpitaux de Paris | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | (patients): * Children with proven metachromatic leukodystrophy (MLD) with decreased activity of arylsulfatase A enzyme in leukocytes and abnormal excretion... | View trial NCT01325025 |
| Assistance Publique – Hôpitaux de Paris | Trial sponsor | Mentioned in trial textTrial free-text mention | Arylsulfatase | View trial NCT01325025 |
| Columbia University | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | Patients must meet the eligibility criteria for organ function regardless of diagnosis: * Age \< 30 or = 30 years of age * Adequate renal function defined... | View trial NCT01019876 |
| Columbia University | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : * Adequate renal function defined as: serum creatinine 2.0 x normal, or creatinine clearance or radioisotope GFR \> 40 ml/min/m2 or \> 40 ml/min/1.73 m2 o... | View trial NCT01050439 |
Showing 5 of 35 sourcing records.
Trial-cited literature (13)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T. | Molecular cancer | 2023 | 111 |
| Chemotherapy-related hyperbilirubinemia in pediatric acute lymphoblastic leukemia: a genome-wide association study from the AIEOP-BFM ALL study group. | Journal of experimental & clinical cancer research : CR | 2023 | 7 |
| Emerging roles of the RNA modifications N6-methyladenosine and adenosine-to-inosine in cardiovascular diseases. | Molecular therapy. Nucleic acids | 2022 | 14 |
| Molecular pathogenesis of rhegmatogenous retinal detachment. | Scientific reports | 2021 | 25 |
| Proteoglycans in Obesity-Associated Metabolic Dysfunction and Meta-Inflammation. | Frontiers in immunology | 2020 | 63 |
Showing 5 of 13 papers.
Literature-extracted relations (2)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Diabetes Mellitus, Type 2 | Disease | associate |
Application of a novel score test for genetic association incorporating gene-gene interaction suggests functionality for prostate cancer susceptibility regions. | 2011 |
| Prostatic Neoplasms | Disease | associate |
Application of a novel score test for genetic association incorporating gene-gene interaction suggests functionality for prostate cancer susceptibility regions. | 2011 |
Organizations publishing (12)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Hospital District of Helsinki and Uusimaa | Hospital | 2 | 2021 to 2022 |
| University of Helsinki | Academic | 2 | 2021 to 2022 |
| Beihang University | Academic | 1 | 2018 |
| Chinese Academy of Medical Sciences & Peking Union Medical College | Academic | 1 | 2023 |
| Christian-Albrechts-Universität zu Kiel | Academic | 1 | 2023 |
Showing 5 of 12 organizations.
Where SULF2 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- immune system disease
- injury, poisoning or other complication
- measurement
- medical procedure
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- reproductive system or breast disease
239 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda biomarker qualification projects, actionable biomarkers, protein variant mentions, and human sample screening reference.